ÇѸ²´ëÇб³¼º½Éº´¿ø

À¯º´Ã¶ ±³¼ö

  • Áø·á°ú ¼ÒÈ­±â³»°ú

Àü¹®Áø·áºÐ¾ß

°£¾Ï, °£°æº¯, °£¿°, Áö¹æ°£

ÀüÈ­ ¿¹¾à 1577-1801
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2025-09-15 ~ 2025-09-20)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ¿Ü·¡Áø·á
¿ÀÈÄ ¿Ü·¡Áø·á¿Ü·¡Áø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

1986¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú ¹Ú»ç

1980¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú ¼®»ç

1977¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú Çлç

°æ·Â

°æ·Â

2015.05 ~ 2025.08°Ç±¹´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú ÀÚ¹®±³¼ö

2002.09 ~ 2015.04»ï¼º¼­¿ïº´¿ø ¼ÒÈ­±â³»°ú ±³¼ö

1995.03 ~ 2002.08Áß¾Ó´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú ±³¼ö

1990.03 ~ 1995.02Áß¾Ó´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú ºÎ±³¼ö

1985.05 ~ 1990.02Áß¾Ó´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú Á¶±³¼ö

1989.09 ~ 1991.02Fox Chase Cancer Center, Philadelphia Postdoctoral Fellow

1978.03 ~ 1982.02¼­¿ï´ëÇб³º´¿ø ·¹Áö´øÆ®

1977.03 ~ 1978.02¼­¿ï´ëÇб³º´¿ø ÀÎÅÏ

ÇÐȸȰµ¿

ÇÐȸȰµ¿

2025 ~ Çѱ¹°£Àç´Ü ÀÌ»çÀå

2011 ~ Á¦2Â÷ ¾Æ½Ã¾ÆÅÂÆò¾ç °£ÇÐȸ °£¾ÏȸÀÇ È¸Àå

2009 ~ 2011´ëÇѰ£ÇÐȸ ÀÌ»çÀå

¼ö»óÀÌ·Â

¼ö»óÀÌ·Â

2017¿¬±¸¾÷Àû»ó (°Ç±¹´ëÇб³º´¿ø)

2004¿ì¼ö³í¹®»ó (»ï¼º»ý¸í°úÇבּ¸¼Ò)

2003¿ì¼ö³í¹®»ó (´ëÇѰ£ÇÐȸ)

2000°úÇбâ¼ú¿ì¼ö³í¹®»ó (´ëÇѰ£ÇÐȸ)

1995Çмú»ó (´ëÇѼÒÈ­±âÇÐȸ)

1985¿ì¼ö³í¹®»ó (´ëÇѼÒÈ­±âÇÐȸ)

³í¹®

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Gut. 2016.6

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
Hepatology. 2007.10

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
Hepatology. 2007.05

A novel parvovirus isolated from Manchurian chipmunks.
Virology. 1999.01

2016 ¼ÒÈ­±â°èÁúȯ Á¦4ÆÇ/±Þ¼º¹ÙÀÌ·¯½º¼º °£¿°(678-695) ÀÏÁ¶°¢